PEN241220P410000
- 0.00
- 0.000.00%
Penumbra Newsroom
Penumbra's Prospective Growth Amidst Market Dynamics Justifies Hold Rating
3 Reasons Growth Investors Will Love Penumbra (PEN)
Form 144 | Penumbra(PEN.US) Insider Proposes to Sell 7.11 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Nov 20, $Penumbra(PEN.US)$ Insider Adam Elsesser intends to sell 30,000 shares of its common stock on Nov 20, with a total market value of approximately $7.11 million. Adam
Penumbra, Inc. to Present at the Piper Sandler 36th Annual Healthcare Conference
Breaking Down Penumbra: 11 Analysts Share Their Views
Penumbra Is Maintained at Overweight by Piper Sandler
Penumbra Analyst Ratings
Piper Sandler Maintains Penumbra(PEN.US) With Buy Rating, Raises Target Price to $250
Express News | Penumbra Inc : Piper Sandler Raises Target Price to $250 From $235
Here's Why You Should Add OMCL Stock to Your Portfolio Now
Penumbra, Inc. (PEN): A Bull Case Theory
Penumbra, Inc.'s (NYSE:PEN) Earnings Haven't Escaped The Attention Of Investors
There May Be Some Bright Spots In Penumbra's (NYSE:PEN) Earnings
Penumbra Reveals Positive Data for Algorithm-assisted Thrombectomy Tech
How Is The Market Feeling About Penumbra?
Truist Financial Maintains Penumbra(PEN.US) With Buy Rating, Announces Target Price $240
Here's Why Penumbra (PEN) Is a Strong Momentum Stock
Penumbra To Present New Late Breaking Data Show Patients Treated With Computer Assisted Vacuum Thrombectomy Technology For Pulmonary Embolism Experience Shorter Hospital Stays And Fewer Complications Compared To Other Treatment Options At The VIVA...
Express News | New Late Breaking Data Show Patients Treated With Penumbra's Computer Assisted Vacuum Thrombectomy Technology for Pulmonary Embolism Experience Shorter Hospital Stays and Fewer Complications Compared to Other Treatment Options
Analysts Conflicted on These Healthcare Names: Penumbra (PEN), Kymera Therapeutics (KYMR) and NovoCure (NVCR)